BioSpace News Archive

SHINE Technologies, LLC (SHINE), a next-generation nuclear technology company, today announced the company has submitted a Drug Master File (DMF) with the U.S. Food and Drug Administration for non-carrier-added lutetium-177 (Lu-177) chloride, a radiopharmaceutical at the forefront of precision cancer treatment.

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced week 240 results from the phase III BRIGHTE study of fostemsavir in heavily treatment-experienced (HTE) adults with multidrug-resistant HIV-1 infection who have very few treatment options left available to them due to resistance, intolerance, or other safety concerns.

CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that the management team will present at the Canaccord Genuity 42nd Annual Growth Conference on Thursday, August 11, 2022.

Salarius Pharmaceuticals, Inc. today announced that the Company will report its second quarter 2022 financial results after the close of the market on Friday, August 5, 2022 and host a conference call and live audio webcast the following Monday, August 8, 2022, at 11:00 a.m. ET, to discuss its financial results.

Q BioMed Inc. (OTCQB: QBIO) a biotech acceleration and commercial stage company focused on licensing and acquiring undervalued biomedical assets in the healthcare sector, has seen an uptick in Strontium89 sales revenue in its recently reported quarter.

Forecast to 2030,’ thoroughly examines the Warts Treatment industry to provide essential data & information for the targeted readers.

Forecast to 2030,’ thoroughly examines the Type 1 Diabetes industry to provide essential data & information for the targeted readers.

Forecast to 2030,’ thoroughly examines the Peanut Allergy industry to provide essential data & information for the targeted readers.

Forecast to 2030,’ thoroughly examines the Lennox Gastaut Syndrome industry to provide essential data & information for the targeted readers.

Forecast to 2030,’ thoroughly examines the Hypercholesterolemia industry to provide essential data & information for the targeted readers.